Gilead Sciences, Inc. (GILD) Earnings Call Transcripts

Gilead Sciences, Inc.'s Latest Earnings Call - Q2 FY2026

In Gilead Sciences' Q2 2026 earnings call, the company reported total product sales of $7.6 billion, reflecting an 8% year-over-year increase, driven by strong performances in the HIV and oncology segments. Notably, the HIV portfolio saw a 12% year-over-year growth, with PrEP sales exceeding $1 billion for the first time. Management raised full-year guidance for HIV sales growth to 9%-10% from 8%, indicating strong momentum in their product offerings. Despite challenges in cell therapy, the overall outlook remains positive with anticipated launches in the second half of the year.

Reported metrics

Guidance from management

Management raised full-year guidance for base business sales growth to approximately 6%-7%, with total product sales expected between $30.1 billion and $30.4 billion, reflecting strong performance across key segments.

What management said

Thanks a lot, Brian. So we continue to have interactions with the FDA as part of normal course of business and questions during a filing and have not seen major changes at this point. I think the components that you're referencing on the earlier lines of therapy, again, we have a dual primary endpoint of both minimal residual disease and PFS and are continuing to progress those endpoints and would plan to file based ...

Yes, Simon, this is Dietmar. Thank you for the question. You're exactly right, right? It's one of those targets that is expressed in non-small cell lung cancer in the non-squamous setting specifically. Obviously, this is early days for us, but what we've seen with TUB-040 in ovarian cancer really encourages us quite a lot. The efficacy that we see, the tolerability that we see we really feel there is an opportunity f...

What analysts pressed on

Analysts expressed concerns about the impact of insurance coverage losses on the HIV treatment market and the competitive pressures affecting cell therapy sales. There were also questions regarding the sustainability of growth in the PrEP segment amidst increasing competition.

Main topics on the call

• HIV Portfolio Growth — Gilead's HIV sales reached $5.7 billion, up 12% year-over-year, driven by Biktarvy and the PrEP business. Management stated, "We are raising our full year HIV growth expectations to 9% to 10% year-over-year from prior gu...
• Trodelvy Performance — Trodelvy sales increased by 26% year-over-year to $457 million, reflecting strong demand in breast cancer treatments. Management highlighted, "We were thrilled to receive back-to-back FDA approvals of Trodelvy in first-l...
• Cell Therapy Challenges — Cell therapy sales declined 14% year-over-year to $417 million, attributed to competitive pressures. Management noted, "We expect cell therapy to decline mid-teens percentage year-over-year."
• Livdelzi Growth — Livdelzi sales more than doubled year-over-year to $167 million, driven by increased demand. Management stated, "Livdelzi continues to gain momentum as the leading second-line treatment for primary biliary cholangitis."

Read the full Gilead Sciences, Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 114 Gilead Sciences, Inc. earnings call transcripts on record, spanning January 13, 2020 to August 4, 2026. Based on this history, Gilead Sciences, Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

GILD

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

114

First call

January 13, 2020

Most recent

August 4, 2026

Reporting cadence

quarterly